---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009109"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:18:46.861722+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows

## Summary
- Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.
- Full year net revenue $31.8M, down 4% due to ThyGeNEXT reimbursement decline ($3.6M impact).
- Full year loss from continuing ops improved to $(5.9)M from $(7.0)M; adjusted EBITDA $(1.2)M vs $(2.0)M.
- Cash balance $4.8M at Dec 31, 2022, up from $2.9M at Dec 31, 2021.
- Management cites expense reductions and volume growth partially offsetting price headwinds.

## SEC filing metadata
- accession: 0001493152-23-009109
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009109
- JSON: https://secwatch.observer/filing/0001493152-23-009109.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009109.txt

## Key facts
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported the fiscal year ended December 31, 2022 results: revenue $31.8 million.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $31.8 million
  - Result: reported results
  source text: Net Revenue was $31.8 million for 2022, a 4% decrease over the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm
- Earnings Releases
  INTERPACE BIOSCIENCES, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.3 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $8.3 million
  - Result: reported results
  source text: Net Revenue was $8.3 million, a decrease of 9% from $9.1 million for the prior year quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1054102/000149315223009109/0001493152-23-009109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.